0 results for 'Sanofi US Services Inc'
Longtime Paris-Based McDermott Partner Joins Rimon in Texas
"Texas is the place to be," said Nicolas Lafont, the latest Rimon lateral hire to cite the firm's rate flexibility as a key reason for his move.Longtime France-Based McDermott Partner Joins Rimon in Texas
"Texas is the place to be," said Nicolas Lafont, the latest Rimon lateral hire to cite the firm's rate flexibility as a key reason for his move.As Eli Lilly's Insulin Pricing Settlement Unravels, Lawyers Vow to Push Ahead
Lawyers touting a $500 million settlement over insulin pricing are back at the drawing board after a judge refused to certify their class.Civil RICO Suit Accuses Big Pharma and Benefit Managers of Insulin Price-Fixing
"Rather than working to lower insulin and other Type 2 diabetes medication prices, major [pharmacy benefit managers] and manufacturers use their dominant market positions to drastically increase the price of these necessary, life-saving medications, generating billions of dollars in illicit profits," co-lead counsel for the plaintiff claimed in a joint statement.Boosted by Litigation, IP and Regulatory Work, Revenue Ticks Up at Wilson Sonsini
Demand varied across the firm's corporate practices, but some areas, such as environmental work, privacy and cybersecurity, were busy.View more book results for the query "Sanofi US Services Inc"
Treatment of Antibody Claims In the U.S. After 'Amgen v. Sanofi'
The future of antibody claiming in the United States is uncertain following the U.S. Supreme Court's ruling in 'Amgen Inc. v. Sanofi,' a highly anticipated decision concerning enablement and whether the traditional way to claim antibodies — claiming antibodies by their function — will survive as a valid claiming strategy.Judge Rejects Class Action Claim Filed Against Novo Nordisk, Eli Lilly and Sanofi-Aventis
"Plaintiffs have not sufficiently shown they failed to receive the benefit of the bargain as they have not alleged that they had 'a reasonable belief about the product induced by a misrepresentation'—and in fact they have asserted the opposite, that their ascertainable loss theory is not based on misrepresentation—or that they were misled into buying insulin that was worth less than was promised," Judge Brian R. Martinotti said.Arnold & Porter Sees Revenue and Profits Jump, With PEP Rising 15% to $1.6M
The environment for counsel on government-facing issues was "quite strong" last year, driving demand across the firm's litigation, transaction and regulatory practices, said chairman Richard Alexander.Deal Watch: Debt Offerings Surge as Markets Begin to Turn
"It is booming right now," said Wachtell partner John Sobolewski of the liability management market.Pharmaceutical Legal and Regulatory Trends To Watch in 2024
This article highlights several notable legal and regulatory developments in 2023 and discusses developments that will continue to shape the pharmaceutical industry in 2024.Revenue, Profit, Cash: Managing Law Firms for Success
Brought to you by Juris Ledger
Download Now
Law Firm Operational Considerations for the Corporate Transparency Act
Brought to you by Wolters Kluwer
Download Now
The Ultimate Guide to Remote Legal Work
Brought to you by Filevine
Download Now
Practical Guidance Journal: Protecting Work Product in a Generative AI World
Brought to you by LexisNexis®
Download Now